Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?
IPI APP by SECURE SYSTEM BYTES
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society
Follicular Lymphoma International Prognostic Index (FLIPI). Online calculator | ClinCaseQuest
Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma Risk Score Calculator: A Tool To Accurat" by Santosh Khanal, Arjun Gampala et al.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma | Haematologica
Diffuse Large B-Cell Lymphoma Risk Score Calculator: A Tool To Accurately Predict Survival Risk And Improve Treatment Decisions
Molecular profiling of large B-Cell lymphomas : A retrospective observational pilot study
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? | Journal of Nuclear Medicine
Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies | Translational Medicine Communications | Full Text
Tool for Capturing DLBCL Prognosis: The Revised International Prognostic Index (R-IPI)
R/R International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B
Overall survival curves of patients with primary gastric diffuse large... | Download Scientific Diagram
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials | Semantic Scholar
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials - Annals of Oncology
A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era | Scientific Reports
Immunohistochemical Distinction Between Diffuse Large B-Cell... | Download Table
Diffuse Large B-cell Lymphoma Prognosis Calculator
Novel prognostic scoring system for diffuse large B-cell lymphoma
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP | Journal of Clinical Oncology
Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study | Anticancer Research
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma - Maurer - 2021 - American Journal of Hematology - Wiley Online Library
Frontiers | A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma
A new prognostic score for AIDS-related lymphomas in the rituximab-era | Haematologica
